Cargando…

Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication

OBJECTIVES: In 2009, the FDA issued a warning that omeprazole–a proton pump inhibitor (PPI)–reduces the antithrombotic effect of clopidogrel by almost half when taken concomitantly. This study aims to analyze the impact of the FDA Safety Communications on prescribing clopidogrel together with PPIs....

Descripción completa

Detalles Bibliográficos
Autores principales:	Guérin, Annie, Mody, Reema, Carter, Valerie, Ayas, Charles, Patel, Haridarshan, Lasch, Karen, Wu, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699636/ https://www.ncbi.nlm.nih.gov/pubmed/26727382 http://dx.doi.org/10.1371/journal.pone.0145504

Ejemplares similares

Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence
por: Mistry, Suresh D., et al.
Publicado: (2011)

The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
por: Sharma, Rakesh K, et al.
Publicado: (2010)

The potential interaction between clopidogrel and proton pump inhibitors: a systematic review
por: Lima, Joao Paulo de Aquino, et al.
Publicado: (2010)

Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials
por: Dunn, Steven P., et al.
Publicado: (2013)

Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel – proton pump inhibitor interaction
por: Kruik‐Kollöffel, Willemien J., et al.
Publicado: (2016)

Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
por: Gurbel, Paul A, et al.
Publicado: (2010)

Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction
por: Lee, Yong Kang, et al.
Publicado: (2023)

Variation in Care for Patients with Irritable Bowel Syndrome in the United States
por: Lacy, Brian E., et al.
Publicado: (2016)

Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs
por: Douglas, Ian J, et al.
Publicado: (2012)

Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
por: Kwan, Joanne, et al.
Publicado: (2011)

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?
por: Kenngott, S, et al.
Publicado: (2010)

Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study
por: Alghamdi, Rahaf A., et al.
Publicado: (2019)

Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events
por: Maret-Ouda, John, et al.
Publicado: (2021)

Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis
por: Pang, Jun, et al.
Publicado: (2019)

Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding
por: Wang, Qing, et al.
Publicado: (2014)

Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome
por: Yan, Yan, et al.
Publicado: (2016)

Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention
por: Lee, Dongyoung, et al.
Publicado: (2021)

Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy
por: Mody, Reema, et al.
Publicado: (2013)

Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System
por: Wang, Liwei, et al.
Publicado: (2017)

Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
por: Cardoso, Rhanderson N, et al.
Publicado: (2015)

Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay
por: Lin, Sheng-Feng, et al.
Publicado: (2020)

Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis
por: Luo, Xiaofeng, et al.
Publicado: (2023)

Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
por: Zeng, Xiaoyu, et al.
Publicado: (2016)

Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis
por: Hu, Wen, et al.
Publicado: (2018)

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer
por: Raoul, Jean-Luc, et al.
Publicado: (2021)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis
por: Li, Mei-Juan, et al.
Publicado: (2017)

Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes
por: Dulai, Parambir S, et al.
Publicado: (2020)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
por: Wu, Bin, et al.
Publicado: (2021)

Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease
por: He, Wanbing, et al.
Publicado: (2021)

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Proton pump inhibitors are associated with increased risk of development of chronic kidney disease
por: Arora, Pradeep, et al.
Publicado: (2016)

Selective Targeting of Virus Replication by Proton Pump Inhibitors
por: Watanabe, Susan M., et al.
Publicado: (2020)

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
por: Wu, Bin, et al.
Publicado: (2021)

Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis
por: Serbin, Michael A., et al.
Publicado: (2016)

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
por: Westergaard, Niels, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a2eiph2gpouv546e0idvj6frpm